4 results
Primary ObjectiveTo evaluate the efficacy of lumacaftor/ivacaftor combination therapy (LUM/IVA) in subjects with cystic fibrosis (CF) 12 years of age and older who have at least one A455E mutation.Other Objectives* To explore the association between…
In this study, we want to investigate the effect of the change in co-medication from lumacaftor to tezacaftor on the kinetics and exposure levels of ivacaftor described by the through concentrationsPrimary Objective: - the through concentration of…
The purpose of this study is to investigate how safe ceftibuten is and how well it is tolerated when it is administered at higher dose levels than those currently available on the market (daily doses up to 400 mg). It will also be investigated how…
In this study we will investigate how safe the new compound VNRX-7145 and the combination of 2 study compounds, the new compound VNRX7145 and the approved compound ceftibuten, are and how well they are tolerated when they are used by healthy…